ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Avoiding Mediastinal Radiation Can Improve Patient Outcomes

April 26, 2013

New Prostate Cancer Detection Group to Study Ultrasound

March 6, 1987

Cancer Prevention: HHS Calls for Warning Labels on Cigars, Says Teen Use High

March 5, 1999

BCDDP Follow Up To Cost $1.6 Million annually For Five Years Okayed; Limited To 59,000 Women

November 3, 1978

Contract Authority Expiration Confuses NCI Money Bill Estimates, Which Range From $605 To $650 Million

June 21, 1974

Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer

January 31, 2003